00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
21:04 , Feb 7, 2019 |  BC Innovations  |  Emerging Company Profile

Tara’s beating heart

Tara Biosystems Inc. is using its heart-on-a-chip platform to uncover cardiac toxicity signals in drug candidates for biopharmas as it ventures into new drug discovery. Tara’s core technology is a 3-D cardiomyocyte culture system that...
22:24 , Dec 20, 2018 |  BC Innovations  |  Emerging Company Profile

KSQ: Widescreen CRISPR

KSQ Therapeutics Inc. is developing therapies using its CRISPRomics technology to identify cancer and immuno-oncology targets by screening all human genes in cancer cell lines and T cells. The company emerged from stealth in 2017...
10:01 , Sep 28, 2018 |  BC Extra  |  Financial News

Flagship leads $80M round for immunotherapy play KSQ

KSQ Therapeutics Inc. (Cambridge, Mass.) plans to use the proceeds from an $80 million series C round to advance its first program -- a modified adoptive T cell immunotherapy -- into the clinic within the...
22:13 , Oct 6, 2017 |  BioCentury  |  Finance

CRISPRing out new targets

Flagship Pioneering believes the CRISPRomics drug discovery technology of recently unveiled KSQ Therapeutics Inc. may have the potential to greatly reduce false positives in drug discovery. On Oct. 2, KSQ emerged from stealth mode with...
18:10 , Oct 6, 2017 |  BC Week In Review  |  Financial News

KSQ debuts with $76M financing

On Oct. 2, CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and...
11:05 , Oct 2, 2017 |  BC Extra  |  Financial News

KSQ debuts with $76M funding

CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and Alexandria Equities. The...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Periodic piece

About a decade after an Arch Venture-led syndicate formed Ikaria Inc. to develop elemental reducing agents for critical care, the firm is going back for round two with the technology. Although the assets have been...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Financial News

Calimmune completes venture financing

Calimmune Inc. , Tucson, Ariz.   Business: Infectious   Date completed: 2015-05-27   Type: Venture financing   Raised: $15 million   Investors: Alexandria Equities; RA Capital Healthcare Fund L.P.; Translational Accelerator LLC; undisclosed pharmaceutical company...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Flex Pharma completes venture financing

Flex Pharma Inc. , Boston, Mass.   Business: Neurology   Date completed: 2014-09-08   Type: Venture financing   Raised: $40 million   Investors: Longwood Fund; Bessemer Venture Partners; EcoR1 Capital; Jennison Associates; Lightstone Ventures; Alexandria...